On November 4, 2024, Waste Management completed its acquisition of all outstanding shares of Stericycle for $62.00 per share in cash. The total enterprise value of the acquisition was $7.2 billion (net of cash acquired). The post-closing operating results of Stericycle have been included in the Consolidated Financial Statements as a new reportable segment referred to as WM Healthcare Solutions.

1. 01

   On November 4, 2024, Waste Management completed its acquisition of all outstanding shares of Stericycle for $62.00 per share in cash. The total enterprise value of the acquisition was $7.2 billion (net of cash acquired). The post-closing operating results of Stericycle have been included in the Consolidated Financial Statements as a new reportable segment referred to as WM Healthcare Solutions.

2. 02

   The company borrowed $5.2 billion under its Term Credit Agreement in October 2024 to fund the Stericycle acquisition and repaid the full amount with net proceeds of approximately $5.2 billion from senior notes issued in November. The company incurred early repayment losses of $7 million in the process.

3. 03

   Waste Management said operating cash flow in 2024 increased $671 million compared with 2023, citing increased earnings in the Collection and Disposal segment and changes in working capital as factors. Acquisition spending in 2024 totaled $7,503 million, of which $7,488 million is included in cash flows from investing activities.

4. 04

   As of December 31, 2024, the Company said debt maturing within 12 months totaled approximately $4.0 billion, of which $2.6 billion was classified as long-term debt based on the Company's intent and ability to refinance it under its $3.5 billion revolving credit facility. The remaining $1.4 billion was classified as current debt.

Key figures

Fiscal year ended December 31, 2024

Revenue

$22.1B

Operating income

$4.1B

Net income

$2.7B

EPS

$6.81

Operating cash flow

$5.4B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.